MedTrace Logo

A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma

NCT07265271 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-12-10

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited.

This study seeks to develop a cell-free tsRNA (cf-tsRNA)-based liquid biopsy assay for accurate detection of early-stage HCC.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DIAGNOSTIC_TEST

Small RNA sequence

Comprehensive small RNA sequencing of serum or plasma-derived cf-tsRNAs to identify candidate biomarkers distinguishing HCC from NDC.

DIAGNOSTIC_TEST

Rt-qPCR

Construction of integrated cf- tsmiRNAs diagnostic classifier using machine learning

DIAGNOSTIC_TEST

Rt-qPCR

PCR-based validation of the tsRNA panel

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2026-06-18
Completion
2026-06-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07265271 on ClinicalTrials.gov